Is early energy supply to patients suffering from acute pancreatitis beneficial?

High versus low energy administration in the early phase of acute pancreatitis: a multicentre randomized double-blind clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN63827758

Enrollment

957

Registered

2017-01-03

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis Digestive System Acute pancreatitis

Interventions

Patients suffering from acute pancreatitis are randomised by computer into two groups: Group A: high energy administration after admission Patients will receive a 10 Ch nasogastric (NG) or nasojejuna

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients above 18 years of age 2. Diagnosed with acute pancreatitis on the basis of the “2 out of 3” rule of the IAP/APA guideline 3. Written informed consent form is signed

Exclusion criteria

Exclusion criteria: 1. Hospitalization 72 hours before admission 2. Abdominal pain >120 hours (5 days) 3. Delirium tremens 4. Child-Pugh C stage liver cirrhosis 5. AP due to malignancy 6. Already on artificial nutrition (enteral or parenteral nutrition) 7. Pregnancy 8. BMI above 40 or below 18 9. Age above 80 years 10. Ketoacidosis 11. Whenever CT with contrast is contraindicated

Design outcomes

Primary

Measure	Time frame
1. Multi organ failure persisting for more than 48h, measured by clinical assessment at admission, daily during the study and at 1-month follow up 3. Mortality, measured at admission, daily during the study and at 1-month follow up	—

Secondary

Measure	Time frame
1. Pancreatic necrosis, measured by CT at admission, daily during the study and at 1-month follow up 2. Nutrition related complications: diarrhoea, aspiration pneumonia, pneumothorax due to central TPN catheter placement, measured by clinical assessment at admission and daily during the study 3. Need for conversion from NG to NJ feeding tube, measured by clinical assessment at admission and daily during the study 4. Need for conversion from enteral nutrition (EN) to total parenteral nutrition (TPN), measured by clinical assessment at admission and daily during the study 5. Days until the start of total feeding, measured daily during the study 6. Use of antibiotics, measured daily during the study 7. Pain relapse, measured using the VAS scale daily during the study 8. C-reactive protein (CRP), measured by laboratory test daily during the study 9. White blood cell (WBC) count, measured by laboratory test daily during the study 10. Procalcitonin (PCT), measured by laboratory test daily during the study 11. Infection, measured by microbiological test daily during the study 12. Length of hospital stay, measured daily during the study 13. Need for ICU admission, measured at admission and daily during the study 14. Length of ICU therapy, measured at admission and daily during the study 15. Organ failure, measured at admission and daily during the study 16. Complications, measured at admission, daily during the study and at 1-month follow up 17. Costs calculation	—

Measure

Time frame

1. Pancreatic necrosis, measured by CT at admission, daily during the study and at 1-month follow up 2. Nutrition related complications: diarrhoea, aspiration pneumonia, pneumothorax due to central TPN catheter placement, measured by clinical assessment at admission and daily during the study 3. Need for conversion from NG to NJ feeding tube, measured by clinical assessment at admission and daily during the study 4. Need for conversion from enteral nutrition (EN) to total parenteral nutrition (TPN), measured by clinical assessment at admission and daily during the study 5. Days until the start of total feeding, measured daily during the study 6. Use of antibiotics, measured daily during the study 7. Pain relapse, measured using the VAS scale daily during the study 8. C-reactive protein (CRP), measured by laboratory test daily during the study 9. White blood cell (WBC) count, measured by laboratory test daily during the study 10. Procalcitonin (PCT), measured by laboratory test daily during the study 11. Infection, measured by microbiological test daily during the study 12. Length of hospital stay, measured daily during the study 13. Need for ICU admission, measured at admission and daily during the study 14. Length of ICU therapy, measured at admission and daily during the study 15. Organ failure, measured at admission and daily during the study 16. Complications, measured at admission, daily during the study and at 1-month follow up 17. Costs calculation

—

Countries

Hungary

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 27, 2026